Given the association between cardiovascular disease and T2D, the potential of IL-1 blocking agents to improve cardiovascular health and glucose metabolism was assessed in the large CANTOS trial, which determined that treatment with the anti-IL-1β monoclonal antibody canakinumab reduces re-occurrence of ischemic events in patients with prior cardiovascular accidents (Ridker et al., 2017). The gene discussed is IL1A; the disease is type 2 diabetes mellitus.